S.Biomedics Co., Ltd.

S.Biomedics Co., Ltd.

KKRX:304360
17,510.00
KRW
-290.00
(-1.63%)
-875.98EPS
266.28BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5,329.36
1,644.76
515.77
525.94
873.22
1,185.05
1,198.96
1,194.67
1,393.53
1,350.47
Basic EPS, GAAP
-3,665
-5,308
-833
-766
-558
-619
-944
-582
-684
-987.38
Free Cash Flow per Basic Share
-4,173.16
-3,067.88
-768.24
-556.32
-371.96
-422.03
-731.37
-450.16
-704.39
-893.58
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-766.37
1,519.07
1,271.99
569.13
245.64
-369.73
618.41
1,010.11
700.56
2,424.98
Tangible Book Value per Share
-1,040.8
1,516.83
1,270.34
567.24
243.15
-384.77
607.93
975.39
674.13
2,389.08
Basic Weighted Avg Shares
1
2
10
10
10
10
11
11
12
12
Sales/Revenue/Turnover
7,633
3,160
5,014
5,319
8,868
12,113
13,108
13,734
16,548
16,492
Operating Margin (%)
-74.64
-186.58
-180.98
-158.54
-52.16
-30.94
-45.68
-39.65
-50.42
-68.42
Depreciation Expense
476
913
1,267
1,349
1,448
1,517
1,553
1,725
2,043
2,413
Net Income, GAAP
-5,250
-10,200
-8,098
-7,747
-5,667
-6,327
-10,321
-6,691
-8,122
-12,058
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-68.77
-322.72
-161.51
-145.64
-63.9
-52.23
-78.74
-48.72
-49.08
-73.11
Working Capital
7,754
13,962
11,886
7,559
10,167
-630
8,048
17,502
7,512
46,448
LT Debt
392
507
1,666
1,177
4,304
7,215
7,305
9,438
7,115
14,625
Total Equity
-7,879
15,264
12,739
4,800
3,832
1,035
12,354
18,311
16,725
39,507
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-56.78
-82.35
-136.11
- -
- -
-70.89
-79.08
-64.15

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,090
3,385
2,806
LT Borrowings
6,030
5,940
13,679
LT Finance Leases
1,084
998
946
Preferred Equity and Hybrid Capital
- -
- -
315
Shares Outstanding
12
12
12
Market Capitalization
470,016
355,453
266,280

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
19,831
15,944
54,805
Cash, Cash Equivalents & STI
14,661
11,136
49,397
Accounts Receivable, Net
1,610
1,921
1,931
Inventories
1,901
1,953
2,235
Total Current Liabilities
12,319
8,541
8,358
Payables & Accruals
- -
- -
- -
ST Debt
5,090
3,385
2,806
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
208%
-8.66%
Free Cash Flow
- -
18.61%
61.63%
Net Income, GAAP
- -
6.83%
21.4%
Sales/Revenue/Turnover
- -
27.36%
20.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,607
3,299
3,378
4,450
13,734
2025
4,462
4,807
3,245
4,034
16,548
2026
4,397
4,816
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-166
-109
-140
-166.42
-582
2025
-193
-253
-198.03
-40.99
-684
2026
-191.31
-552
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
52
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Seoul South Korea
IPO Date
May 4, 2023
Business
S.Biomedics Co., Ltd. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the research, development, and commercialization of advanced stem cell therapies and regenerative medicine products. Founded in 2005 and headquartered in Seoul, South Korea, the company develops novel therapeutics based on two proprietary biological platforms: Targeted Embryonic Stem Cell Differentiation (TED) technology, which standardizes the high-purity differentiation of pluripotent stem cells into specific neural cell types; and Functionally Enhanced Cell Spheroid (FECS) technology, a three-dimensional cell spheroid culture method engineered to enhance cell viability, paracrine secretion, and tissue engraftment. S.Biomedics operates across the biotechnology, regenerative medicine, and medical aesthetics sectors, targeting intractable neurological, vascular, and degenerative conditions for healthcare institutions and aesthetic clinics in South Korea and global markets. The company's core product and development portfolio comprises clinical-stage cell therapy pipeline programs, including TED-A9, a human embryonic stem cell-derived dopaminergic neural precursor cell therapy for the treatment of Parkinson's disease; TED-N, a stem cell-derived neural progenitor cell therapy for subacute spinal cord injury; FECS-Ad, an adipose-derived stem cell spheroid therapy for critical limb ischemia; and FECS-DF, a dermal fibroblast spheroid treatment for deep tissue regeneration and wrinkle correction; early-stage research programs, including TED-R for macular degeneration, CF-TED-N for ischemic stroke, and CF-FECS-DF for intractable wound healing; and aesthetic medical products and cosmeceuticals commercialized through its subsidiary, S.THEPHARM Co., Ltd., consisting of the QTFill line of cross-linked hyaluronic acid dermal fillers; QTL and QTL 365 polydioxanone lifting threads; and QTCell and QTOn cell culture-derived anti-aging topical solutions. In recent developments, S.Biomedics completed its initial public offering on the KOSDAQ market of the Korea Exchange under the ticker symbol 304360. The company established a strategic development and manufacturing partnership with Catalent, Inc. to support global supply and regulatory compliance for its lead asset. In clinical advancements, S.Biomedics announced successful long-term Phase 1/2a clinical trial results for TED-A9, demonstrating favorable safety and significant motor improvement in patients with Parkinson's disease, and initiated regulatory preparations for an Investigational New Drug application with the United States Food and Drug Administration to expand into multi-regional registrational clinical trials. The company has also raised growth capital via convertible bond issuances to fund late-stage clinical programs and expanded out-licensing discussions with global pharmaceutical partners.